Surgery for obstructive hypertrophic cardiomyopathy: challenge and future.
10.3760/cma.j.cn112139-20220918-00397
- Author:
Hui Ming GUO
1
;
Pei Jian WEI
1
Author Information
1. Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangzhou 510080, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Cardiomyopathy, Hypertrophic/surgery*;
Heart Septum/surgery*;
Mitral Valve/surgery*;
Mitral Valve Insufficiency/surgery*;
Treatment Outcome
- From:
Chinese Journal of Surgery
2023;61(3):181-186
- CountryChina
- Language:Chinese
-
Abstract:
After more than 60 years of development, with the deepening of the pathophysiological understanding of obstructive hypertrophic cardiomyopathy, the extent and resection thickness of myectomy have increased significantly. Myectomy combined with the correction of anomalies of the mitral valve apparatus has become the standard treatment of obstructive hypertrophic cardiomyopathy. Only a few centers worldwide can routinely perform it due to the difficulty. Because of the advances of new drugs and interventional therapy, the development of surgical treatment faces many challenges. At the same time, generations of cardiovascular surgeons are constantly trying to promote septal myectomy, including developing devices and the surgical field, as well as improving surgical planning by advanced technology. At present, the superior long-term efficacy of septal myectomy has been confirmed. It is necessary to work together to promote the treatment of hypertrophic obstructive cardiomyopathy, so as to guard people's health.
